These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 414273)

  • 1. 6-Hydroxydopamine inhibits some effects of mescaline centrally administered to rabbits.
    Ferri S; Reina RA; Braga P
    Psychopharmacology (Berl); 1977 Dec; 55(2):147-9. PubMed ID: 414273
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Naloxone potentiates the disruptive effects of mescaline on operant responding in the rat.
    Commissaris RL; Moore KE; Rech RH
    Pharmacol Biochem Behav; 1980 Oct; 13(4):601-3. PubMed ID: 7433492
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cross tolerance to antinociception elicited by intracerebroventricular administration of mescaline and morphine to rabbits, and EEG correlates.
    Ferri S; Santagostino A; Braga PC
    Psychopharmacology (Berl); 1976 Jun; 47(3):267-9. PubMed ID: 823562
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of mescaline and its derivative N-[3,4,5-trimethoxyphenylethyl]-aziridine on the spatial orientation of rats in a T-maze.
    Koupilová M; Herink J
    Physiol Bohemoslov; 1989; 38(6):497-502. PubMed ID: 2534189
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiovascular and behavioral effects of intracisternal 6-hydroxydopamine in the rabbit.
    Korner PI; Oliver JR; Reynoldson JA; Head GA; Carson VJ; Walker MM
    Eur J Pharmacol; 1978 Dec; 53(1):83-93. PubMed ID: 738362
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of central pretreatment with 6-hydroxydopamine on the hypotensive effect of clonidine.
    Warnke E; Hoefke W
    Arzneimittelforschung; 1977; 27(12):2311-3. PubMed ID: 580043
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of 6-hydroxydopamine to deplete brain catecholamines in the rhesus monkey: effects on urinary catecholamine metabolites and behavior.
    Kraemer GW; Breese GR; Prange AJ; Moran EC; Lewis JK; Kemnitz JW; Bushnell PJ; Howard JL; McKinney WT
    Psychopharmacology (Berl); 1981; 73(1):1-11. PubMed ID: 6785782
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of intraventricular 6-hydroxydopamine on cerebrovascular CO2 reactivity in anesthetized rats.
    Edvinsson L; Hardebo JE; MacKenzie ET
    Acta Physiol Scand; 1977 Sep; 101(1):122-5. PubMed ID: 906856
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of tolerance to the antinociceptive effect of mescaline intraventricularly administered to rabbits.
    Ferri S; Santagostino A; Braga PC
    Psychopharmacology (Berl); 1976 Jun; 47(3):261-5. PubMed ID: 823561
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of simultaneous local injection of 6-hydroxydopamine and naloxone on the testis of neonatal rats.
    Gerendai I; Nemeskéri A; Csernus V; Halász B
    Andrologia; 1989; 21(5):449-55. PubMed ID: 2510556
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effects of intraventricular 6-hydroxydopamine on body temperature and arterial blood pressure in cats and rabbits.
    Lewis PJ; Rawlins MD; Reid JL
    Br J Pharmacol; 1974 Jun; 51(2):207-12. PubMed ID: 4451740
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mescaline elicits behavioral effects in cats by an action at both serotonin and dopamine receptors.
    Trulson ME; Crisp T; Henderson LJ
    Eur J Pharmacol; 1983 Dec; 96(1-2):151-4. PubMed ID: 6581976
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Change of preoptic opiate receptors after injection of 6-OHDA into sublocus coeruleus in the rabbit].
    Zhu JM; He XP; Li KY; Huang DK; Cao XD
    Sheng Li Xue Bao; 1990 Apr; 42(2):114-20. PubMed ID: 2165279
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Short- and long-term effects of intraventricular 6-hydroxydopamine in rats pretreated with a monoamine oxidase inhibitor.
    Vetulani J; Reichenberg K; Wiszniowska G; Marchaj J
    Pol J Pharmacol Pharm; 1977; 29(6):645-56. PubMed ID: 564059
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 6-hydroxydopamine treatments enhance behavioral responses to intracerebral microinjection of D1- and D2-dopamine agonists into nucleus accumbens and striatum without changing dopamine antagonist binding.
    Breese GR; Duncan GE; Napier TC; Bondy SC; Iorio LC; Mueller RA
    J Pharmacol Exp Ther; 1987 Jan; 240(1):167-76. PubMed ID: 3100767
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The effect of 6-hydroxydopamine on the behavior of rats with differing resistance to stress exposure].
    Gromova EA; Semenova TP; Gasanov GG; Ismaĭlova KhIu; Fast AE; Nesterova IV
    Zh Vyssh Nerv Deiat Im I P Pavlova; 1990; 40(2):301-9. PubMed ID: 2166392
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reversal of the 6-hydroxydopamine-induced suppression of a CAR by drugs facilitating central catecholaminergic mechanisms.
    Ruiz M; Monti JM
    Pharmacology; 1975; 13(4):281-6. PubMed ID: 1187753
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alteration by pretreatment with iproniazid and an inactive mescaline analogue of a behaviour change induced by mescaline.
    Smythies JR; Johnston VS; Bradley RJ
    Nature; 1967 Oct; 216(5111):196-7. PubMed ID: 6057240
    [No Abstract]   [Full Text] [Related]  

  • 19. Effects of neonatal 6-hydroxydopamine treatment on catecholamine levels and behavior during development and adulthood.
    Fobes JL; Olds ME
    Psychopharmacology (Berl); 1981; 73(1):27-30. PubMed ID: 6785785
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differences in tolerance to mescaline produced by peripheral and direct central administration.
    Tilson HA; Sparber SB
    Psychopharmacologia; 1971; 19(4):313-23. PubMed ID: 5109405
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.